Your browser doesn't support javascript.
loading
Guiding pragmatic treatment choices for rifampicin-resistant tuberculosis in the absence of second-line drug susceptibility testing.
Achar, Jay; Seddon, James A; Knight, Gwenan M; Dodd, Peter J; Esmail, Hanif; Hughes, Jennifer; McQuaid, C Finn.
Afiliação
  • Achar J; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden jay.achar@ki.se.
  • Seddon JA; Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • Knight GM; Section of Paediatric Infectious Disease, Department of Infectious Disease, Imperial College London, London, UK.
  • Dodd PJ; TB Modelling Group, TB Centre, Centre for Mathematical Modelling of Infectious Diseases and AMR Centre, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Esmail H; School of Health and Related Research, University of Sheffield, Sheffield, UK.
  • Hughes J; MRC Clinical Trials Unit, University College London, London, UK.
  • McQuaid CF; Institute for Global Health, University College London, London, UK.
Eur Respir J ; 62(5)2023 11.
Article em En | MEDLINE | ID: mdl-37945035

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Plantas_medicinales Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia

Texto completo: 1 Base de dados: MEDLINE Métodos Terapêuticos e Terapias MTCI: Plantas_medicinales Assunto principal: Tuberculose Resistente a Múltiplos Medicamentos / Mycobacterium tuberculosis Idioma: En Revista: Eur Respir J Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suécia